DUBLIN, Aug. 22, 2023 /PRNewswire/ — Medtronic plc (NYSE:MDT) today announced financial results for its first quarter of fiscal year 2024 (FY24), which ended July 28, 2023. Key Highlights Revenue of $7.7 billion increased 4.5% as reported and 6.0% organic GAAP diluted earnings per share (EPS) of $0.59 decreased 16%; non-GAAP diluted EPS of $1.20 increased 6% Company increases […]
Financial
Advanced NanoTherapies (ANT) Secures $4M Strategic Investment to Accelerate Clinical Development of SirPlux Duo Drug-Coated Balloon (DCB) for Treating de novo Coronary Artery Disease (CAD)
LOS GATOS, Calif., Aug. 22, 2023 /PRNewswire/ — Advanced NanoTherapies Inc. (ANT), a clinical-stage medical device company committed to solving the most significant challenges in vascular disease through the creative applications of nanotechnology, today announced a $4M Series A extension from a prominent undisclosed strategic medical device company. Additionally, ANT successfully treated the first cohort of […]
Expanse Medical Welcomes Shlomi Nachman to Board of Directors
PLEASANTON, Calif., Aug. 21, 2023 /PRNewswire/ — Expanse Medical, the innovative medical device incubator founded by Eitan Konstantino with focus on global innovations, proudly announces the addition of Shlomi Nachman to its Board of Directors and the Board of its spinoff, Expanse ICE. Mr. Nachman’s distinguished career includes his recent tenure as Johnson & Johnson […]
Medtronic announces cash dividend for second quarter of fiscal year 2024
DUBLIN, Aug. 17, 2023 /PRNewswire/ — The board of directors of Medtronic plc (NYSE:MDT) on Thursday, August 17, 2023, approved an increase in the company’s cash dividend for the second quarter of fiscal year 2024 versus the prior year, raising the quarterly amount to $0.69 per ordinary share. This quarterly declaration is consistent with the first […]
Silence Therapeutics Reports Second Quarter 2023 Results
LONDON–(BUSINESS WIRE)–Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today reported its financial results for the second quarter ended June 30, 2023 and reviewed recent business highlights. “Silence’s strong second quarter […]
Hyperfine, Inc. Reports Second Quarter 2023 Financial Results
GUILFORD, Conn., Aug. 14, 2023 (GLOBE NEWSWIRE) — Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that created the Swoop® system, the world’s first FDA-cleared portable, point-of-care MRI system, today announced second quarter 2023 financial results and provided a business update. “We made solid progress at Hyperfine in the […]
Aziyo Biologics Reports Second Quarter 2023 Financial Results – Transformation Continues to Drug-Eluting Biomatrix Company
SILVER SPRING, Md., Aug. 14, 2023 (GLOBE NEWSWIRE) — Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, today provided a business update and reported financial results for the second quarter ended June […]
LianBio Reports Second Quarter 2023 Financial Results and Provides Corporate Update
SHANGHAI, China and PRINCETON, N.J., Aug. 14, 2023 (GLOBE NEWSWIRE) — LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today reported financial results for the second quarter ended June 30, 2023. “During the first half of 2023, we achieved […]
DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2023 Financial Results
MINNEAPOLIS–(BUSINESS WIRE)–DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, today provided a business update and financial results for the quarter ended June 30, 2023. Management will host a conference call Tuesday, August 15, 2023, at 7:00AM Central Time/8:00AM […]
HDL Therapeutics to Go Public in Merger with Swiftmerge Acquisition Corp.
NEW YORK & VERO BEACH, Fla.–(BUSINESS WIRE)–HDL Therapeutics, Inc. (“HDL Therapeutics”), a privately held commercial stage biotech company with an FDA-approved cardiovascular therapy the Plasma Delipidation System (PDS-2™ System) for reducing coronary atheroma in patients with homozygous familial hypercholesterolemia (HoFH), has signed a definitive merger agreement with Swiftmerge Acquisition Corp. […]
